Open AccessObinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis
Author(s) -
Marco Bellone,
Lorenzo Pradelli,
Stefano Molica,
Adele Emanuela De Francesco,
Daniela Ghislieri,
Emanuele Guardalben,
A. Caputo
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s317885
Subject(s) - medicine , rituximab , obinutuzumab , follicular lymphoma , oncology , hazard ratio , lymphoma , confidence interval
To assess the cost-effectiveness of obinutuzumab (O-chemo) in comparison to rituximab (R-chemo) in patients with untreated advanced follicular lymphoma (FL) at intermediate or high risk from an Italian National Health Service (NHS) perspective.